Valuation: Pulmonx Corporation

Market Cap 110M 98.61M 90.12M 82.27M 155M 10.34B 160M 1.09B 433M 5.51B 413M 404M 17.41B P/E 2026 *
-2.64x
P/E 2027 * -2.9x
Enterprise Value 110M 98.61M 90.12M 82.27M 155M 10.34B 160M 1.09B 433M 5.51B 413M 404M 17.41B EV / Sales 2026 *
1.21x
EV / Sales 2027 * 1.12x
Free-Float
95.42%
Yield 2026 *
-
Yield 2027 * -
1 day+0.98%
1 week-14.14%
Current month-14.14%
1 month+44.94%
3 months+25.85%
6 months+100.00%
Current year+16.74%
1 week 2.48
Extreme 2.48
3.13
1 month 1.72
Extreme 1.72
3.25
Current year 1.13
Extreme 1.13
3.25
1 year 1.13
Extreme 1.13
3.25
3 years 1.13
Extreme 1.13
14.84
5 years 1.13
Extreme 1.13
45.49
10 years 1.13
Extreme 1.13
69.48
Manager TitleAgeSince
Chief Executive Officer 64 2025-10-26
Director of Finance/CFO 53 2019-04-30
Chief Tech/Sci/R&D Officer - 2020-02-29
Director TitleAgeSince
Director/Board Member 72 2007-01-31
Chairman 66 2019-09-30
Director/Board Member 64 2014-12-17
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Sell

Chief Technology Officer

-14,245 0.0332%
9/1/26 Sell

Chief Executive Officer

-41,882 0.0975%
9/1/26 Sell

Executive/Senior Manager

-7,879 0.0183%
Change 5-day change 1-year change 3-year change Capi.($)
+1.17%-14.14%+42.54%-73.15% 110M
-2.33%+4.28%-11.37%+16.57% 197B
-2.27%+11.66%-7.89%+17.72% 128B
-2.04%+6.23%+13.87%+39.68% 128B
+0.96%+5.15%-38.02%+12.24% 99B
-1.18%+1.54%-6.75%+70.62% 64.82B
-0.44%+7.37%+19.78%-18.00% 58.17B
+0.87%+22.85%-5.13%+60.08% 52.84B
-6.98%-14.94%-9.70%+46.32% 50.69B
-2.36%+3.72%+3.27%-8.07% 37.23B
Average -1.43%+4.42%+0.06%+16.40% 81.55B
Weighted average by Cap. -1.71%+7.56%-6.32%+25.22%

Financials

2026 *2027 *
Net sales 91.03M 81.65M 74.62M 68.12M 128M 8.56B 132M 899M 359M 4.57B 342M 334M 14.41B 98.6M 88.43M 80.82M 73.78M 139M 9.27B 143M 974M 388M 4.95B 370M 362M 15.61B
Net income -41.31M -37.05M -33.86M -30.91M -58.23M -3.88B -60.07M -408M -163M -2.07B -155M -152M -6.54B -40.16M -36.02M -32.92M -30.05M -56.61M -3.77B -58.4M -397M -158M -2.01B -151M -147M -6.36B
Net Debt - -
Projected Income Statement - Annual - Pulmonx Corporation
Logo Pulmonx Corporation
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
Employees
296
Date Price Change Volume
26-11-06 US$2.580 +0.78% 307,045
26-11-05 US$2.560 -9.54% 742,450
26-11-04 US$2.830 +4.04% 984,142
26-11-03 US$2.720 +5.43% 744,084
26-11-02 US$2.580 -14.14% 1,437,254
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Pulmonx Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.560USD
Average target price
3.700USD
Spread / Average Target
+44.53%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Pulmonx Corporation
  1. Stock Market
  2. Stocks
  3. LUNG Stock